While there are no clear definitions of recovery, it is clear that the goals of recovery depend on the severity of acute kidney injury and the clinical context. The degree of renal recovery affects both renal and clinical prognosis. There are presently few guidelines on recovery targets, which range in extent from dialysis independence via normalization of serum creatinine to recovery of renal functional reserve. However, while there are no validated biomarkers for predicting recovery, evidence suggests that both functional and damage biomarkers can aid the assessment of recovery.
Given the ubiquitous failure of intervention trials to ameliorate acute kidney injury (AKI), the focus of clinical studies must inevitably shift to trials for the prevention of AKI or acceleration of recovery. However, recovery after AKI is difficult to define, as it encompasses multiple parameters ranging from structural and metabolic recovery of injured kidney cells to whole organ functional recovery. The context of AKI is important in selecting an appropriate definition of recovery. A quantifiable assessment of recovery may involve functional or biochemical biomarkers ( Table 1) .
The current functional parameters for determining recovery are usually limited to surrogate markers of glomerular filtration, such as serum creatinine and urine output. These are clearly inadequate even with respect to glomerular function, given the known limitations of these surrogate markers. Nevertheless, creatinine remains widely available. As creatinine-based consensus definitions of AKI have facilitated much progress in understanding AKI, the 16th Acute Disease Quality Initiative proposed definitions and staging criteria for acute kidney disease (AKD) and renal recovery [1] . AKI and AKD were recognized as a continuum. Persistent AKI was defined as AKI lasting more than 48 h and characterized by serum creatinine or urine output criteria and AKD as AKI criteria lasting more than 7 days after an exposure. A minimum of 48 h was deemed necessary to separate two distinct episodes of AKI. Recovery from AKD was operationally defined as a reduction in peak AKI stage (based on KDIGO criteria). However, it was recognized that this could be further refined by change in serum creatinine level, glomerular filtration rate (GFR), biomarkers of injury or repair, and/or return of renal reserve.
Current approaches for measuring GFR with inulin, 51 Cr-EDTA, 99 TmDTPA or iohexol are laborious and unsuitable for use in patients in the intensive care unit. Calculation of the estimated GFR (eGFR), for example, by using the chronic kidney disease epidemiology collaboration (CKD-EPI) equations is validated in patients with CKD in an outpatient setting, because serum creatinine is likely to be in "steady-state"; however, eGFR is not valid in the ICU setting when creatinine is changing. The kinetic eGFR can provide a closer approximation to true GFR under non-steady state conditions [2] and has been useful in predicting recovery 4-8 h after kidney transplantation when serum creatinine was not predictive [3] , but KeGFR has not been validated under ICU conditions and requires an estimate of baseline eGFR, which may be unknown. Serum creatinine trajectories provide a loose measure of change direction without need for a baseline creatinine and a "resolving AKI phenotype" (defined as a decrease in SCr of 0.3 mg/dL or 25% from maximum in the first 72 h) was associated with a low risk of death [4] . However, clinical utility remains limited by the usual inherent uncertainty in any single serum creatinine measurement. Short-timed urine creatinine clearance (CCr) can be used to estimate GFR [5] . However, several limitations exist in the use of CCr in ICU patients. For instance, CCr often overestimates GFR, as creatinine is also secreted in the tubules, and establishing steady state conditions is often not possible in AKI and muscle mass may be lost rapidly.
Finally, creatinine and urine output provide minimal insight into the renal structure. A major disconnect between glomerular function and renal structure is well described, such that more than 50% structural loss is required for an increase in serum creatinine. Given that the prevalence of overt CKD in most populations is at least 10% [6] , there is likely to be an even greater prevalence of subclinical CKD, defined as severe parenchymal damage in the presence of a normal serum creatinine [7] . Thus, a return to previous or normal creatinine-baseline values after AKI provides no insight into how much acute parenchymal damage remains, and does not exclude the development of chronic changes that characterize maladaptive repair, such as loss of the microvasculature with tubular atrophy and parenchymal fibrosis [8] .
Clearly, these limitations also apply to studies that refer to recovery within 10% baseline serum creatinine, or within 90% eGFR which is derived from creatinine. The recent new Acute Disease Quality Initiative definitions recognized the potential limitations of a purely serum creatinine-based definition of AKI by defining subacute AKI and subacute AKD. Such "subclinical" phenotypes represent renal parenchymal damage without an increase in creatinine that triggered the diagnosis of AKI and were present before or after a clinically overt episode of AKI [1, 7] and can be further sub-phenotyped as: A No evidence of injury, B damage biomarker or loss of renal reserve present, or C creatinine not back to baseline.
It is, therefore, important to consider which other biomarkers could facilitate assessment and understanding of renal recovery. At a functional level, a better measure of renal recovery would be a comparison between the directly measured true GFR with the pre-AKI level. However, an even better measure would be a comparison of the renal functional reserve with the pre-AKI level, as a loss of renal functional reserve could indicate the presence of subclinical CKD, since reserve reflects the renal hemodynamic response to physiological stress(es). While direct measurement of GFR is possible, current methods are slow, expensive, labor-intensive, and relatively inaccurate whether performed by CCr or by radio-isotope clearance. Furthermore, measurement of renal reserve is not yet standardized and therefore rarely performed. At present, renal reserve is measured by determining the difference between the resting and stress GFR from the endogenous creatinine CCr before and after an oral protein load consumed after an 8-h fast and accompanied by adequate oral hydration [9] . Hourly CCr measurements are used and continued for at least 3 h. Consequently, they are subject to the same constraints and limitations as short duration CCr measurements following supervised voiding [5] . Nevertheless, a recent study showed that low reserve predicted AKI following cardiac bypass with an AUC of 0.83 (95% CI 0.70-0.96) [9] . This was similar to the immediate postoperative predictive performance of the urinary cell-cycle arrest biomarkers insulin-like growth factor binding protein-7, and tissue inhibitor of metalloproteinase-2, (AUC 0.87 [95% CI 0.79-0.84]) [9] . It remains to be seen whether AKI reduces renal reserve, which seems likely if AKI has produced unresolved injury or subclinical CKD. A decrease in kidney damage biomarkers has been used to predict recovery after AKI in both native kidneys and after transplantation. A persistent increase in damage markers is presumed to signal continuing renal injury, although it is not clear if the same stimulus for biomarker elevation persists when levels remain increased. Nevertheless, persistence provides information about recovery since it suggests "non-recovery" and may also reflect the risk of progression to AKD or CKD. Thus, many papers refer to persistent high levels of damage biomarkers as predicting "recovery" when they actually refer to non-recovery. A further caveat is that a decrease of damage biomarkers in the absence of continuing injury does not equal cellular regeneration and recovery. The need for regeneration biomarkers foreshadowed in Table 1 remains critical for progress. Indeed, while a decrease in damage biomarker concentrations such as NGAL in dialysis-dependent AKI in the ICU [10] , or a decrease of clusterin or insulin-like growth factor binding protein-7 x tissue inhibitor of metalloproteinase-2 after kidney transplantation [11] can herald respectively eventual or imminent recovery of kidney function, these biomarkers are not in the causal pathway of recovery (as opposed to "injury") and are thus not ideal biomarkers for this purpose.
Early biomarker studies have been summarized elsewhere [12] . These can be loosely categorized into mechanisms such as inflammatory markers (e.g., NGAL, IL-6, IL-18), cell damage markers (e.g., KIM-1, L-FABP), or as markers of cell-cycle arrest. As such, damage biomarkers potentially provide mechanistic information that may eventually allow timely individualization of therapy. The main recent novel damage biomarkers of note in predicting recovery from AKI vary with the settings in which they have been studied (Table 2) .
There is presently no consensus on the appropriate timing of biomarkers to predict recovery. The appropriate timing of biomarker measurements to predict recovery depends on the context. AKI severity ranges from anuric dialysis-dependent subjects to Stage 1 AKI subjects with normal urine output. Early AKI also includes "biomarker positive-creatinine negative" subjects at risk of progression to stage 3 [13] , a category likely to become accepted in consensus guidelines as damage biomarker availability increases. This has already proven useful in triaging after cardiopulmonary bypass [14] . While there are currently no validated markers that predict wellness or useful regeneration after AKI, a repair phase protein, YKL-40 appears to have the potential. Also known as breast regression protein-39 in mice, YKL-40 is a glycoprotein involved in inflammation, cytoprotection, and repair and is produced by a variety of cells including renal macrophages. High urinary YKL-40 in deceased kidney donors was not only associated with AKI but also with reduced frequency of delayed graft function and improved eGFR in recipients at 6 months, possibly suggesting that elevation of this marker may represent onset of effective repair.
In conclusion, renal recovery after AKI is undergoing careful evaluation. Biomarkers will play a critical role in understanding as well as documenting recovery.
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